ClinicoEconomics and Outcomes Research (Aug 2020)
Real-World Characterization of Women with Diagnosed Endometriosis Initiating Therapy with Elagolix Using a US Claims Database
Abstract
Eric S Surrey,1 Ahmed M Soliman,2 Beverly Johns,2 Jamie B Vora,3 Hugh S Taylor,4 Sanjay K Agarwal5 1Colorado Center for Reproductive Medicine, Lone Tree, CO, USA; 2Health Economics and Outcomes Research, AbbVie Inc, North Chicago, IL, USA; 3Healthcare Solutions, AbbVie Inc, North Chicago, IL, USA; 4Department of Obstetrics and Gynecology and Reproductive Sciences, Yale School of Medicine, New Haven, CT, USA; 5Center for Endometriosis Research and Treatment, University of California, San Diego, CA, USACorrespondence: Eric S SurreyColorado Center for Reproductive Medicine, 10290 RidgeGate Circle, Lone Tree, CO 80124, USATel +1 (303)-788-8300Email [email protected]: Elagolix is an oral gonadotropin-releasing hormone antagonist approved in the United States for the management of moderate to severe pain associated with endometriosis. We performed a real-world evaluation of the demographic and clinical characteristics of women diagnosed with endometriosis who were initiating elagolix therapy in the United States.Patients and Methods: This retrospective cohort database analysis included women 18– 49 years of age with ≥ 1 pharmacy claim for elagolix between August 2018 and December 2019 from the Copyright © 2020 Truven Health Analytics LLC. All Rights Reserved. Women had continuous medical and pharmacy health plan enrollment during the baseline period (year immediately preceding the index date [date of earliest elagolix claim]) and had ≥ 1 medical claim with endometriosis (International Classification of Diseases [ICD]-9/10 code [617.x and N80.x]) on or before the index date. Baseline demographics, comorbidities, ICD code-based endometriosis anatomic site, endometriosis-related treatments, and pain symptoms were summarized descriptively.Results: The study included 2083 patients with mean age at baseline of 33.2 ± 8.1 years. Comorbidities most commonly recorded were non-cancer, non-endometriosis pain (59.5%), including arthritis/joint pain (43.7%) and back/neck pain (31.7%), and mental disorder (40.7%), including anxiety (32.7%). The majority of endometriosis diagnosis codes recorded referred to unspecified location (52.3%) and pelvic peritoneum (23.0%); 61.0% of patients received a medical endometriosis-related treatment in the baseline period, with the most common treatments being contraceptives (various routes of administration, 40.2%) and progestins (31.7%). Additionally, 35.4% of the patients received an endometriosis-related surgery during baseline, with the most common being laparoscopy (33.2% of all patients). Opioids were used during the baseline period by 57.3% of the patients. For pain symptoms, 71.5%, 30.4%, and 19.3% of the patients had claims for pelvic pain, dysmenorrhea, and dyspareunia, respectively.Conclusion: Endometriosis therapies were used by a significant proportion of patients with endometriosis in the year immediately preceding elagolix initiation.Keywords: gonadotropin-releasing hormone antagonist, women’s health, clinical characteristics, demographics
